Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 déc. 2023 16h02 HE
|
Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
12 déc. 2023 07h57 HE
|
Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).
Global Enzymatic DNA Synthesis Market Analysis, Trends and Forecasts to 2028 - Opportunities in CRISPR-Cas9 Integration and Cell-Free Synthetic Biology
12 déc. 2023 05h23 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Enzymatic DNA Synthesis Market: Analysis By Product Type (DNA Library Synthesis and Custom DNA Synthesis), By Technology (PCR, CRISPR, SOLA and...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
21 nov. 2023 12h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
16 nov. 2023 06h00 HE
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester
14 nov. 2023 05h30 HE
|
Research Nester
New York, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The global genome editing market size is slated to expand at ~21.1% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 69.6...
Epic Bio to Participate in Upcoming Investor Conference
07 nov. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
World-Leading Gene Editing Technology Unveiled in United Kingdom
23 oct. 2023 12h38 HE
|
Research and Markets
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- In a momentous stride toward the future of agriculture, scientists have recently achieved a remarkable breakthrough in the realm of gene editing. The...
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...